Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marco Angelo

Showing results (31-40 of 66) with videos related to

Pageof 7
Sort By:
Frontiers in Immunology|June 14, 2021
Case Report: Circulating Myeloid-Derived Suppressive-Like Cells and Exhausted Immune Cells in Non-Small Cell Lung Cancer Patients Treated With Three Immune Checkpoint InhibitorsGiuseppe Bronte, Alberto Verlicchi, Serena De Matteis, et al.
Radiation Oncology (London, England)|June 26, 2019
Accelerated hypofractionated radiotherapy plus chemotherapy for inoperable locally advanced non-small-cell lung cancer: final results of a prospective phase-II trial with a long-term follow-upElisabetta Parisi, Giovenzio Genestreti, Anna Sarnelli, et al.
Nuclear Medicine Communications|October 17, 2014
111In-Pentetreotide (OctreoScan) scintigraphy in the staging of small-cell lung cancer: its accuracy and prognostic significanceGiovenzio Genestreti, Alberto Bongiovanni, Marco Angelo Burgio, et al.
Annals of Surgical Oncology|February 24, 2016
Erratum to: Oncoplastic Breast-Conserving Surgery for Tumors Larger than 2 Centimeters: Is it Oncologically Safe? A Matched-Cohort AnalysisFrancesca De Lorenzi, Pietro Loschi, Vincenzo Bagnardi, et al.
Annals of Surgical Oncology|February 5, 2016
Oncoplastic Breast-Conserving Surgery for Tumors Larger than 2 Centimeters: Is it Oncologically Safe? A Matched-Cohort AnalysisFrancesca De Lorenzi, Pietro Loschi, Vincenzo Bagnardi, et al.
Cancers|February 25, 2023
Malignant Pleural Mesothelioma: Preliminary Toxicity Results of Adjuvant Radiotherapy Hypofractionation in a Prospective Trial (MESO-RT)Elisabetta Parisi, Donatella Arpa, Giulia Ghigi, et al.
Lung Cancer (Amsterdam, Netherlands)|February 24, 2020
Impressive clinical response to anti-PD-1 therapy in epithelioid mesothelioma with high clonal PD-L1 expression and EML4-ALK rearrangementGiuseppe Bronte, Angelo Delmonte, Marco Angelo Burgio, et al.
Breast (Edinburgh, Scotland)|February 13, 2007
Neoadjuvant therapy in locally advanced breast cancer: 99mTc-MIBI mammoscintigraphy is not a reliable technique to predict therapy responseLaura Lavinia Travaini, Silvia Melania Baio, Marta Cremonesi, et al.
Biochimica Et Biophysica Acta|February 11, 2014
Targeting bone metastatic cancer: Role of the mTOR pathwayFrancesco Bertoldo, Franco Silvestris, Toni Ibrahim, et al.
Oncology Letters|February 13, 2016
Appropriate use of tumour biomarkers for treatment with innovative drugs: A retrospective studyIlaria Massa, Oriana Nanni, Massimo Guidoboni, et al.
Pageof 7

Showing results (31-40 of 66) with videos related to

Sort By:
Pageof 7
Frontiers in Immunology|June 14, 2021
Case Report: Circulating Myeloid-Derived Suppressive-Like Cells and Exhausted Immune Cells in Non-Small Cell Lung Cancer Patients Treated With Three Immune Checkpoint InhibitorsGiuseppe Bronte, Alberto Verlicchi, Serena De Matteis, et al.
Radiation Oncology (London, England)|June 26, 2019
Accelerated hypofractionated radiotherapy plus chemotherapy for inoperable locally advanced non-small-cell lung cancer: final results of a prospective phase-II trial with a long-term follow-upElisabetta Parisi, Giovenzio Genestreti, Anna Sarnelli, et al.
Nuclear Medicine Communications|October 17, 2014
111In-Pentetreotide (OctreoScan) scintigraphy in the staging of small-cell lung cancer: its accuracy and prognostic significanceGiovenzio Genestreti, Alberto Bongiovanni, Marco Angelo Burgio, et al.
Annals of Surgical Oncology|February 24, 2016
Erratum to: Oncoplastic Breast-Conserving Surgery for Tumors Larger than 2 Centimeters: Is it Oncologically Safe? A Matched-Cohort AnalysisFrancesca De Lorenzi, Pietro Loschi, Vincenzo Bagnardi, et al.
Annals of Surgical Oncology|February 5, 2016
Oncoplastic Breast-Conserving Surgery for Tumors Larger than 2 Centimeters: Is it Oncologically Safe? A Matched-Cohort AnalysisFrancesca De Lorenzi, Pietro Loschi, Vincenzo Bagnardi, et al.
Cancers|February 25, 2023
Malignant Pleural Mesothelioma: Preliminary Toxicity Results of Adjuvant Radiotherapy Hypofractionation in a Prospective Trial (MESO-RT)Elisabetta Parisi, Donatella Arpa, Giulia Ghigi, et al.
Lung Cancer (Amsterdam, Netherlands)|February 24, 2020
Impressive clinical response to anti-PD-1 therapy in epithelioid mesothelioma with high clonal PD-L1 expression and EML4-ALK rearrangementGiuseppe Bronte, Angelo Delmonte, Marco Angelo Burgio, et al.
Breast (Edinburgh, Scotland)|February 13, 2007
Neoadjuvant therapy in locally advanced breast cancer: 99mTc-MIBI mammoscintigraphy is not a reliable technique to predict therapy responseLaura Lavinia Travaini, Silvia Melania Baio, Marta Cremonesi, et al.
Biochimica Et Biophysica Acta|February 11, 2014
Targeting bone metastatic cancer: Role of the mTOR pathwayFrancesco Bertoldo, Franco Silvestris, Toni Ibrahim, et al.
Oncology Letters|February 13, 2016
Appropriate use of tumour biomarkers for treatment with innovative drugs: A retrospective studyIlaria Massa, Oriana Nanni, Massimo Guidoboni, et al.
Pageof 7